aTyr Pharma Q2 FY26 net loss narrows to $10.31 million
ATYR•Clinical program timing
Protocol for a planned Phase 3 efzofitimod study in pulmonary sarcoidosis was submitted in June; FDA feedback is expected by end-August, while SSc-ILD Phase 2 topline data are due in Q1 2027.
Cash position and restructuring update
Cash, cash equivalents, restricted cash and investments ended June 30 at USD 58.91 million, with runway into late 2028 based on current operations.
Restructuring includes a roughly 60% workforce cut, targeting about USD 13 million in annualized operating expense savings starting in Q4 2026.
Q2 FY26 loss narrows as expenses decline
aTyr Pharma posted a GAAP net loss attributable to shareholders of USD 10.31 million, narrowing from USD 19.53 million a year earlier; GAAP EPS improved to a loss of USD 0.11.
GAAP operating loss tightened to USD 10.88 million from USD 20.31 million, while R&D expense fell to USD 6.75 million from USD 15.38 million.
